Combination Of Irinotecan And Cisplatin For Treatment Of Small-cell Lung Cancer

Objective:To evaluate the eficacy and adverse events of irinotecan(CPT-11) combined with cisplatin (DDP)in the treatment of patients with small cell lung cancer (SCLC),and compare the eficacy of regimen (first-line irinotecan/cisplatin (IP) second-line etoposide/cisplatin (EP) with regimen (first-line EP second-line IP) in the treatment of small cell lung cancer.Methods:Fifty patients with untreated or first-line EP treatment of small cell lung cancer were enrolled onto the study.。CPT-1160mg/m2was administered intravenously on days1,8, and15in combination with cisplatin60mg/m2(total) on day1,2, and3every28days.Results:The overall response rate in patients was69.38%(limited disease(LD),69.56%, extensive disease(ED)69.23%); The median response duration was7.0months for LD patients and4.0months for ED patients. The median survival was25.1 months for LD patients and13.0months for ED patients. The major grade3or4toxicities were neutropenia (55.81%), leukopenia (41.86%), diarrhea (20.93%), and nausea/vomiting (18.66%). the overall survival of first-line EP second-line IP group comparing with first-line IP second-line EP group has significant difference (10.0months vs25.1months, P=0.021). Grade3and4thrombocytopenia favored the first-line EP second-line IP group (P=0.01)Conclusion:Irinotecan plus cisplatin is an effective treatment for small-cell lung cancer., toxicity can be tolerated. For small cell lung cancer patients,the regimen of first-line IP second-line EP may be a better choice than first-line EP second-line IP.However, this conclusion requires further study with more samples.